About us
We care what you care
TrustBio pioneers cutting-edge molecular POCT technologies combining eLAMP amplification, microfluidic cartridges, and AI-driven interpretation. From infectious disease detection to oncology and nutritional precision care, we offer a full-stack diagnostic ecosystem that empowers real-time decisions at any location — no central lab required.
Your beloved pet deserves the best care!
"When they're feeling unwell, they can't tell you what's wrong" EZCheck Rapid Molecular Detection System is designed specifically for pet health, offering a quick and easy testing solution. With results in just 15 minutes, it provides real-time, in-clinic pathogen detection for precise, on-the-spot diagnosis. Maximize every golden moment of treatment - EZCheck empowers veterinarians to make fast, accurate diagnoses and provide immediate medical care to protect your pet's health and happiness.
VIEW MORE

LATEST NEWS

General Inquiries

info@trustbioo.com

Sales Inquiries

sales@trustbioo.com

+886-2 2697-3756

+886-2 2697-3656

19F-8., No. 95, Sec. 1, Xintai 5th Rd., Xizhi Dist.,

New Taipei City 221416 , Taiwan (R.O.C.)

256 bit SSL Encryption
Recommend usfing Chrome, Firefox, Safari latest version of the browser.

TrustBio’s EZCheck Feline Respiratory Infection Panel 1 Featured on Taiwan’s AgTech News


TrustBio has developed the “EZCheck Feline Respiratory Infection Panel 1,” which simultaneously detects three major pathogens — Feline Herpesvirus (FHV-1), Feline Calicivirus (FCV), and Mycoplasma felis. The kit features simple operation, rapid reaction, and is well-suited for frontline clinical use.

Test results demonstrate that the assay achieves over 95% analytical specificity, maintains high sensitivity even at low sample concentrations, and delivers accuracy consistent with qPCR results within 35 cycles. Further validation using clinical samples showed a 95% concordance rate for both positive and negative results, indicating that the test provides not only laboratory-level accuracy but also strong applicability in real clinical settings.

This innovation is expected to enhance diagnostic efficiency and reduce the risk of antimicrobial resistance. Building on these promising results, TrustBio plans to further develop a rapid nucleic acid detection platform, highlighting significant potential for future applications.